mTOR inhibitors in urinary bladder cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Urinary bladder cancer treatment faces challenges with existing drugs showing limited efficacy and high recurrence rates.
• The mammalian target of rapamycin (mTOR) pathway is frequently dysregulated in various cancers.
• mTOR inhibitors represent a promising class of anticancer agents.

Purpose of the Study:

• To review the mTOR pathway and evaluate the efficacy of mTOR inhibitors (sirolimus, everolimus, temsirolimus) alone and in combination with cisplatin and gemcitabine.
• To investigate the effects of these drug combinations on urinary bladder tumor cell lines.
• To assess the potential of mTOR inhibitors in overcoming current treatment limitations for bladder cancer.

Main Methods:

• In vitro evaluation of mTOR inhibitors (sirolimus, everolimus, temsirolimus) and non-mTOR inhibitors (cisplatin, gemcitabine) on urinary bladder tumor cell lines (5637, T24, HT1376).
• Assessment of mTOR and AKT phosphorylation changes following drug exposure.
• Analysis of cell proliferation inhibition and antiproliferative effects of drug combinations.

Main Results:

• The non-muscle-invasive cell line 5637 showed minor alterations in mTOR/AKT phosphorylation and slight proliferation inhibition upon exposure to rapalogs.
• Combinations of gemcitabine with everolimus or temsirolimus demonstrated encouraging and more effective responses in 5637 and T24 cell lines.
• Cisplatin combined with everolimus or temsirolimus exhibited promising antiproliferative effects, particularly in 5637 and HT1376 cell lines.

Conclusions:

• Everolimus or temsirolimus, when used in conjunction with gemcitabine or cisplatin, could play a significant role in treating urinary bladder cancer.
• The effectiveness of these combinations may depend on tumor grading.
• Further research into mTOR inhibitor combinations offers a potential avenue for improving bladder cancer therapy.